Trevena, Inc. Boasting a stellar management team and board of directors, Trevena is at the forefront of innovative drug development programs that address urgent diseases in the CNS field and beyond. Trevena's diverse pipeline is based on groundbreaking science, leveraging Nobel Prize-winning research.

The company has successfully obtained FDA approval for OLINVYK® (oliceridine) injection, a groundbreaking medication that empowers patients. Moreover, Trevena is actively pursuing three investigational drugs: TRV250 for acute migraine treatment, TRV734 for maintenance therapy of opioid use disorder, and TRV045, a novel S1P receptor modulator that holds the potential to revolutionize the treatment of diabetic neuropathic pain, epilepsy, and other CNS disorders. Guided by an unwavering commitment to patient care, Trevena employs a team of passionate industry experts who operate with integrity, transparency, and respect.

Their shared mission is to deliver novel medicines that fulfill the critical needs of patients worldwide. © 2023 Trevena, Inc. All Rights Reserved